滴糖醇激酶:看看免疫疗法的未来
Miguel Martin-Salgado1, Ane Ochoa-Echeverría1, Isabel Mérida1
1Department of Immunology and Oncology. National Centre for Biotechnology. Spanish Research Council (CNB-CSIC), Spain.
Advances in biological regulation
|November 10, 2023
概括
糖醇激酶 (DGKs) 抑制T细胞反应,这对抗癌症免疫至关重要. 抑制DGKs可以增强T细胞激活,提供一种新的免疫治疗策略来对抗癌症进展和转移.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 癌症仍然是导致死亡的主要原因,瘤对传统治疗产生抵抗力.
- 免疫疗法,特别是基于T细胞的方法,为癌症控制提供了一个有希望的替代方案.
- 瘤细胞通过各种机制逃避免疫监测,阻碍有效的T细胞反应.
研究的目的:
- 审查二甲基甘油激酶 (DGKs) 在调节T细胞激活和效应器功能的作用.
- 探索DGK抑制作为一种增强抗瘤免疫力的策略的潜力.
- 阐明DGKs调节T细胞信号通路的分子机制.
主要方法:
- 对T细胞DGK功能的现有文献的综述.
- 通过DGKs调节的信号通路的分析,包括PLCγ/Ras/ERK.
- 检查涉及DGK异型操纵的研究 (例如,敲击小鼠).
主要成果:
- 通过抑制PLCγ/Ras/ERK通路,DGKα和DGKζ异型减弱T细胞激活.
- 调节DGKs导致T细胞受体信号传递和能量受损.
- 对DGKs的生殖线淘汰导致增强的抗瘤特性和改善的免疫反应.
结论:
- DGKs作为T细胞激活和效应因子功能的负调节者.
- 抑制DGKs是一种潜在的治疗策略,可以重振T细胞对抗癌症的反应.
- 进一步了解DGK介导信号对于开发新的DAG促进免疫疗法至关重要.
相关概念视频
IP3/DAG Signaling Pathway
12.1K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.1K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Amplifying Signals via Second Messengers
7.0K
Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...
7.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


